116 related articles for article (PubMed ID: 38659267)
21. Anlotinib suppresses the DNA damage response by disrupting SETD1A and inducing p53-dependent apoptosis in Transformed Follicular Lymphoma.
Zhuang X; Yao J; Li X; Jiang Y; Zhong M; Tan J; Zhou H; Li G; Zha J; Xu B
Int J Med Sci; 2024; 21(1):70-79. PubMed ID: 38164353
[No Abstract] [Full Text] [Related]
22. Anlotinib exerts potent antileukemic activities in Ph chromosome negative and positive B-cell acute lymphoblastic leukemia via perturbation of PI3K/AKT/mTOR pathway.
Chen Q; Lai Q; Jiang Y; Yao J; Chen Q; Zhang L; Wang C; Zhou Y; Deng M; Xu B
Transl Oncol; 2022 Nov; 25():101516. PubMed ID: 35985203
[TBL] [Abstract][Full Text] [Related]
23. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
[TBL] [Abstract][Full Text] [Related]
24. Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy.
Hu X; Xia M; Wang J; Yu H; Chai J; Zhang Z; Sun Y; Su J; Sun L
Biomed Pharmacother; 2020 Sep; 129():110397. PubMed ID: 32585451
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of Prostate Cancer DU-145 Cells Proliferation by
Li X; Tang Y; Yu F; Sun Y; Huang F; Chen Y; Yang Z; Ding G
Mar Drugs; 2018 Sep; 16(9):. PubMed ID: 30208576
[TBL] [Abstract][Full Text] [Related]
26. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.
Rahmani M; Aust MM; Benson EC; Wallace L; Friedberg J; Grant S
Clin Cancer Res; 2014 Sep; 20(18):4849-60. PubMed ID: 25070836
[TBL] [Abstract][Full Text] [Related]
27. 8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma.
Dennison JB; Shanmugam M; Ayres ML; Qian J; Krett NL; Medeiros LJ; Neelapu SS; Rosen ST; Gandhi V
Blood; 2010 Dec; 116(25):5622-30. PubMed ID: 20844237
[TBL] [Abstract][Full Text] [Related]
28. Dihydrocelastrol exerts potent antitumor activity in mantle cell lymphoma cells via dual inhibition of mTORC1 and mTORC2.
Xie Y; Li B; Bu W; Gao L; Zhang Y; Lan X; Hou J; Xu Z; Chang S; Yu D; Xie B; Wang Y; Wang H; Zhang Y; Wu X; Zhu W; Shi J
Int J Oncol; 2018 Aug; 53(2):823-834. PubMed ID: 29901111
[TBL] [Abstract][Full Text] [Related]
29. Resveratrol potentiates the anti-tumor effects of rapamycin in papillary thyroid cancer: PI3K/AKT/mTOR pathway involved.
Bian P; Hu W; Liu C; Li L
Arch Biochem Biophys; 2020 Aug; 689():108461. PubMed ID: 32531316
[TBL] [Abstract][Full Text] [Related]
30. Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.
Guo H; Zeng D; Zhang H; Bell T; Yao J; Liu Y; Huang S; Li CJ; Lorence E; Zhou S; Gong T; Jiang C; Ahmed M; Yao Y; Nomie KJ; Zhang L; Wang M
Oncogene; 2019 Mar; 38(11):1802-1814. PubMed ID: 30361685
[TBL] [Abstract][Full Text] [Related]
31. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma.
Rudelius M; Pittaluga S; Nishizuka S; Pham TH; Fend F; Jaffe ES; Quintanilla-Martinez L; Raffeld M
Blood; 2006 Sep; 108(5):1668-76. PubMed ID: 16645163
[TBL] [Abstract][Full Text] [Related]
32. The combined effect and mechanism of antiangiogenic drugs and PD-L1 inhibitor on cell apoptosis in triple negative breast cancer.
Li J; Zhang D; Liu Z; Wang Y; Li X; Wang Z; Liang G; Yuan X; Li Y; Komorowski AL; Rozen WM; Orlandi A; Takabe K; Franceschini G; Jerusalem G; Wang X
Ann Transl Med; 2023 Jan; 11(2):83. PubMed ID: 36819490
[TBL] [Abstract][Full Text] [Related]
33. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
[TBL] [Abstract][Full Text] [Related]
34. Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approach.
Chaturvedi NK; Rajule RN; Shukla A; Radhakrishnan P; Todd GL; Natarajan A; Vose JM; Joshi SS
Mol Cancer Ther; 2013 Oct; 12(10):2006-17. PubMed ID: 23963361
[TBL] [Abstract][Full Text] [Related]
35. Class IA PI3K inhibition inhibits cell growth and proliferation in mantle cell lymphoma.
Tabe Y; Jin L; Konopleva M; Shikami M; Kimura S; Andreeff M; Raffeld M; Miida T
Acta Haematol; 2014; 131(1):59-69. PubMed ID: 24052005
[TBL] [Abstract][Full Text] [Related]
36. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
[TBL] [Abstract][Full Text] [Related]
37. Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia.
van Attekum MHA; Terpstra S; Slinger E; von Lindern M; Moerland PD; Jongejan A; Kater AP; Eldering E
Oncogene; 2017 Jun; 36(26):3651-3660. PubMed ID: 28192408
[TBL] [Abstract][Full Text] [Related]
38. Anlotinib Suppresses Oral Squamous Cell Carcinoma Growth and Metastasis by Targeting the RAS Protein to Inhibit the PI3K/Akt Signalling Pathway.
Lu Y; Lin J; Duan M; Rui Y; Zheng H; Zhu L; Zhu X; Wei J
Anal Cell Pathol (Amst); 2021; 2021():5228713. PubMed ID: 34926131
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
40. Targeting the PI3K/Akt/mTOR signaling pathway by pterostilbene attenuates mantle cell lymphoma progression.
Yu D; Zhang Y; Chen G; Xie Y; Xu Z; Chang S; Hu L; Li B; Bu W; Wang Y; Xiao W; Sun X; Chang G; Gao L; Qiang S; Wu X; Zhu W; Shi J
Acta Biochim Biophys Sin (Shanghai); 2018 Aug; 50(8):782-792. PubMed ID: 29961897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
